The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
 
Kevin Kim
Research Funding - AstraZeneca; Hoosier Foundation; Koo Foundation; Replimune; TriSalus Life Sciences
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Davendra Sohal
Consulting or Advisory Role - AADi; AstraZeneca; Cancer Commons; Elevar Therapeutics; Totus Medicines; TransThera Biosciences; Valar Labs
Speakers' Bureau - Genentech; Incyte; Seagen
Research Funding - AADi (Inst); Ability Pharma (Inst); Amgen (Inst); Apexigen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bexion (Inst); Bristol-Myers Squibb (Inst); FibroGen (Inst); Genentech (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst); Mirati Therapeutics (Inst); NextCure (Inst); Pancreatic Cancer Action Network (Inst); Regeneron (Inst); Roche (Inst)
 
Julien Edeline
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Basilea; Bayer; BeiGene; Boston Scientific; Bristol-Myers Squibb; BTG; Eisai; Incyte; Ipsen; Merck Serono; MSD; Roche; SERVIER; Taiho Oncology
Research Funding - Beigene (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Exeliom Biosciences
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Jeong Heo
Consulting or Advisory Role - AstraZeneca/MedImmune
Speakers' Bureau - AstraZeneca/MedImmune; Roche
 
Aditya Bhansali
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Shaheen Kumar
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Guy Ungerechts
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; The Sander Foundation
Patents, Royalties, Other Intellectual Property - 4 IP families re: oncolytic MeV
Expert Testimony - Goverment
Other Relationship - CanVirex